By Kamal Choudhury Feb 9 (Reuters) - Privately held Iambic said on Monday it has entered a multi-year partnership worth more ...

In the pursuit of solutions to complex global challenges including disease, energy demands, and climate change, scientific ...

A team of biochemists at the University of California, Santa Cruz, has developed a faster way to identify molecules in the ...

NorthStrive Biosciences Inc. (“NorthStrive Biosciences”), a subsidiary of PMGC Holdings Inc. (NASDAQ:ELAB) (“PMGC”), today ...

AI boosts efficiency in early, high-failure R&D, improving success rates and capital efficiency across biotech and pharma.

Digital twins revolutionize drug discovery by integrating AI and biological data, enhancing prediction, trial design, and decision-making in precision medicine.

As China's new drug R&D enters the 'deep waters' of homogeneous competition, the path for followers has become increasingly ...

Outsourcing is driving biopharma efficiency and scale, including in the drug discovery area and early phase development.

Syngene collaborates with Johns Hopkins University to accelerate early-stage drug discovery programs and platform technologies.

Insilico Medicine ('Insilico', 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence ...

For patients taking medications that don't work as expected or pharmaceutical companies struggling with clinical trial ...

Iambic’s physics-informed NeuralPLexer is intended to enhance protein–ligand modeling, enabling broader exploration of ...